Hostname: page-component-848d4c4894-pftt2 Total loading time: 0 Render date: 2024-05-15T19:50:20.226Z Has data issue: false hasContentIssue false
  • English
  • Français

The role of depot neuroleptics in the treatment of schizophrenic patients1

Published online by Cambridge University Press:  09 July 2009

Jerome Levine ,
Nina R. Schooler  and
Giovanni B. Cassano
Jerome Levine*
Affiliation:
Psychopharmacology Research Branch, National Institute of Mental Health, Rockville, Maryland, USA, and the Institute of Clinical Psychiatry, University of Pisa, Italy
Nina R. Schooler
Affiliation:
Psychopharmacology Research Branch, National Institute of Mental Health, Rockville, Maryland, USA, and the Institute of Clinical Psychiatry, University of Pisa, Italy
Giovanni B. Cassano
Affiliation:
Psychopharmacology Research Branch, National Institute of Mental Health, Rockville, Maryland, USA, and the Institute of Clinical Psychiatry, University of Pisa, Italy
*
2Address for correspondence: Dr Jerome Levine, Psychopharmacology Research Branch, National Institute of Mental Health, 5600 Fishers Lane, Rockville, Maryland 20857, USA.
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Conference Report
Information
Psychological Medicine , Volume 9 , Issue 2 , May 1979 , pp. 383 - 386
Copyright
Copyright © Cambridge University Press 1979

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

1

This paper was presented at the 11th Congress of the Collegium Internationale Neuropsychopharmacologicum, Vienna, 9–14 July 1978.

References

Crawford, R. & Forrest, A. (1974). Controlled treatment of depot fluphenazine in outpatient schizophrenics. British Journal of Psychiatry 124, 385–391.Google Scholar
del Guidice, J., Clark, W. G. & Gocka, E. F. (1975). Prevention of recidivism of schizophrenics treated with fluphenazine enanthate. Psychosomatics 16, 32–36.CrossRefGoogle Scholar
Falloon, I. R. H., Watt, D. C. & Shepherd, M. (1978). A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychological Medicine 8, 265–274.CrossRefGoogle ScholarPubMed
Hogarty, G. E., Schooler, N. R. & Ulrich, R. (1979). Depot fluphenazine and social therapy in the after care of schizophrenic patients: relapse analyses of a two year controlled trial. Archives of General Psychiatry (in the press).CrossRefGoogle Scholar
Rifkin, A., Quitkin, F. & Rabiner, C. F. (1977). Fluphenazine decanoate, fluphenazine hydrochloride given orally and placebo in remitted schizophrenics: 1. Relapse rates after one year. Archives of General Psychiatry 34, 43–47.Google Scholar
Schooler, N. R. & Levine, J. (1976). The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine. Pharmakopsychiatrie Neuro-Psychopharmakologie 9, 159–169.Google Scholar
Schooler, N. R., Levine, J. & Severe, J. B. (1979). Depot fluphenazine in the prevention of relapse in schizophrenia: evaluation of a treatment regime. Psychopharmacology Bulletin (in the press).Google Scholar
Simon, P., Fermanian, J. & Ginestet, D. (1978). Standard and long-acting neuroleptics in chronic schizophrenics: an 18-month open multicenter study. Archives of General Psychiatry 35, 893–897.CrossRefGoogle Scholar